

PRESERVING & RESTORING VISION OF PATIENTS WITH RETINAL DISORDERS

Introduction

jCyte is a late-stage biotechnology company with a mission to preserve and restore vision in patients with retinitis pigmentosa and other degenerative retinal disorders via its novel cellular therapy, jCell.

Challenges

Manufacturing the jCell therapy requires a complex, multi-step process in which cell aggregates are produced. Precise counting and analysis of the cells that comprise the aggregates are vital to the final stages of successful manufacturing runs of the therapy.

User Commentary

“Using ChemoMetec’s NucleoCounter® NC-200™ reliable automated cell counters within our manufacturing runs has improved the overall efficiency and precision of counting and analyzing the cells within the aggregates produced in the jCell manufacturing process.

Such efficiency and precision are critical to ensure jCyte has sufficient stock of its therapy for its single pivotal Phase 3 trial, and ultimately, to immediately meet global demand upon commercialization for a patient population with significant unmet medical needs.”

— Victor Chao, Vice President of Chemistry, Manufacturing and Controls (CMC) Operations at jCyte.

COUNT AGGREGATED CELLS CONSISTENTLY

- Dedicated, straightforward assay for counting aggregated cells
- Minimal variation between users and sites
- Standardizes cell counting processes
- Expedites time-to-market
- Easy validation and incorporation into SOPs
- 21 CFR Part-11 ready software



NucleoCounter® NC-200™